Research Progress on the Effects and Mechanisms of Curcumin Against Breast Cancer
DOI:
https://doi.org/10.63313/hmt.2001Keywords:
Curcumin, Breast Cancer, Antitumor Mechanism, Apoptosis, Angiogenesis, Tumor Immune MicroenvironmentAbstract
Curcumin is a natural lipophilic polyphenolic compound extracted and isolated from the dried rhizome of Curcuma longa L., a plant of the genus Curcuma in the family Zingiberaceae. It exhibits a variety of pharmacological activities, including anti-inflammatory, antioxidant, immunomodulatory, and antitumor effects, and has shown significant application value in the adjuvant treatment of various diseases. In recent years, the potential of curcumin in the field of oncology has attracted considerable attention. Studies have confirmed that curcumin possesses significant therapeutic potential against breast cancer, playing important roles in multiple key biological processes such as inhibiting cell proliferation, inducing apoptosis, blocking invasion and metastasis, suppressing angiogenesis, and regulating the tumor immune microenvironment. This article systematically reviews relevant domestic and international literature to summarize the research progress on the effects and mechanisms of curcumin against breast cancer, aiming to provide a reference for further research on curcumin and the development of novel anti-breast cancer drugs.
References
[1] Chinese Anti-Cancer Association, Committee of Breast Cancer Society. Guidelines for the standardized diagnosis and treatment of advanced breast cancer in China (2024 edition)[J]. Chinese Journal of Oncology, 2024, 46(10): 895-912.
[2] Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, Huang L, Liu CC, Shao ZM, Yu KD. Breast cancer: pathogenesis and treatments[J]. Signal Transduction and Targeted Therapy, 2025, 10(1): 49. doi: 10.1038/s41392-024-02108-4.
[3] Fu M, Peng Z, Wu M, Lv D, Li Y, Lyu S. Current and future burden of breast cancer in Asia: A GLOBOCAN data analysis for 2022 and 2050[J]. Breast, 2025, 79: 103835. doi: 10.1016/j.breast.2024.103835.
[4] Galuia M, Fedorova J, McHayleh W, Mamounas E, Ahmad S, Pavri S. Perioperative drug management of systemic therapies in breast cancer: A literature review and treatment recommendations[J]. Current Oncology, 2025, 32(3): 154. doi: 10.3390/curroncol32030154.
[5] He T, Yu S, Wu C. Progress of traditional Chinese medicine in regulating immune cell in the tumor microenvironment of triple-negative breast cancer[J]. Integrative Cancer Therapies, 2025, 24: 15347354251349824. doi: 10.1177/15347354251349824.
[6] Wu HC, Tsai CC, Hsu PC, Kuo CY. Herbal medicine in breast cancer therapy: Mechanisms, evidence, and future perspectives[J]. Current Issues in Molecular Biology, 2025, 47(5): 362. doi: 10.3390/cimb47050362.
[7] Nass N, Ignatov A, Kalinski T. Interplay of interleukin-1β and curcumin on VEGF expression in breast cancer cells[J]. Oncology Research, 2026, 34(3): 13. doi: 10.32604/or.2025.072793.
[8] Golmohammadi M, Zamanian MY, Al-Ani AM, Jabbar TL, Kareem AK, Aghaei ZH, Tahernia H, Hjazi A, Jissir SA, Hakimizadeh E. Targeting STAT3 signaling pathway by curcumin and its analogues for breast cancer: A narrative review[J]. Animal Models and Experimental Medicine, 2024, 7(6): 853-867. doi: 10.1002/ame2.12491.
[9] Wali AF, Talath S, El Tanani M, Rashid Rangraze I, Babiker R, Shafi S, Bansal R. PI3K/AKT/mTOR pathway in breast cancer pathogenesis and therapy: Insights into phytochemical-based therapeutics[J]. Nutrition and Cancer, 2025, 77(9): 938-958. doi: 10.1080/01635581.2025.2521884.
[10] Liu S, Zhou S, Wang B, Jia Z. Effects of curcumin nanoparticles on the proliferation and migration of human ovarian cancer cells assessed through the NF-κB/PRL-3 signaling pathway[J]. International Immunopharmacology, 2024, 141: 112964. doi: 10.1016/j.intimp.2024.112964.
[11] Chen C, Wang Q, Liu J. Curcumin inhibits growth and triggers apoptosis in human castration-resistant prostate cancer cells via IGF-1/PI3K/Akt pathway[J]. Journal of International Medical Research, 2025, 53(2): 3000605231220807. doi: 10.1177/03000605231220807.
[12] Sarkar E, Kotiya A, Bhuyan R, Raza ST, Misra A, Ahmad R, Mahdi AA. Curcumin chemo-sensitizes intrinsic apoptosis through ROS-mediated mitochondrial hyperpolarization and DNA damage in breast cancer cells[J]. Cellular Signalling, 2025, 128: 111637. doi: 10.1016/j.cellsig.2025.111637.
[13] Wang S, Wang X, Zheng X, Jiang H, Liu L, Ma N, Dong X. NGR-modified curcumin nanovesicles reverse immunotherapy resistance in triple-negative breast cancer via TLR9 and mTOR pathway modulation[J]. Cell Biology and Toxicology, 2025, 41(1): 109. doi: 10.1007/s10565-025-10055-1.
[14] Poma P, Massaro M, Rigogliuso S, Condorelli L, Sánchez-Espejo R, Viseras C, Notarbartolo M, Riela S. Curcumin and doxorubicin encapsulated in biocompatible clay-based nanomaterial: A strategy to overcome multidrug resistance[J]. Archiv der Pharmazie, 2025, 358(1): e2400702. doi: 10.1002/ardp.202400702.
[15] Wang S, Wang X, Zheng X, Jiang H, Liu L, Ma N, Dong X. NGR-modified curcumin nanovesicles reverse immunotherapy resistance in triple-negative breast cancer via TLR9 and mTOR pathway modulation[J]. Cell Biology and Toxicology, 2025, 41(1): 109. doi: 10.1007/s10565-025-10055-1.
[16] Qiao X, Zheng K, Ye L, Yang J, Cui R, Shan Y, Li X, Li H, Zhu Q, Zhao Z, Ge RS, Wang Y. NL13, a novel curcumin analogue and polo like kinase 4 inhibitor, induces cell cycle arrest and apoptosis in prostate cancer models[J]. British Journal of Pharmacology, 2024, 181(22): 4658-4676. doi: 10.1111/bph.16501.
[17] Veselá K, Kejík Z, Masařík M, Babula P, Dytrych P, Martásek P, Jakubek M. Curcumin: A potential weapon in the prevention and treatment of head and neck cancer[J]. ACS Pharmacology & Translational Science, 2024, 7(11): 3394-3418. doi: 10.1021/acsptsci.4c00518.
[18] Bhattacharjya D, Sivalingam N. Mechanism of 5-fluorouracil induced resistance and role of piperine and curcumin as chemo-sensitizers in colon cancer[J]. Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397(11): 8445-8475. doi: 10.1007/s00210-024-03189-2.
[19] Yakubu J, Natsaridis E, du Toit T, Barata IS, Tagit O, Pandey AV. Nanoparticles with curcumin and piperine modulate steroid biosynthesis in prostate cancer[J]. Scientific Reports, 2025, 15(1): 13613. doi: 10.1038/s41598-025-98102-z.
[20] Chen C, Wang Q, Liu J. Curcumin inhibits growth and triggers apoptosis in human castration-resistant prostate cancer cells via IGF-1/PI3K/Akt pathway[J]. Journal of International Medical Research, 2025, 53(2): 3000605231220807. doi: 10.1177/03000605231220807.
[21] Ding J, Liu Z, Liu S, Xie X, Yin Q, Lu W, Wang W, Zhang Y. Preparation and anti-tumor ability evaluation of anti-PD-L1 conjugated curcumin in colon cancer[J]. International Journal of Biological Macromolecules, 2025, 306(Pt 3): 141563. doi: 10.1016/j.ijbiomac.2025.141563.
[22] Zheng H, Li S, Wang Y, Su S, Wang Y, Wang F. Curcumin inhibits colorectal cancer progression by targeting PTBP1 and CDK2-mediated pathways[J]. Frontiers in Oncology, 2025, 15: 1566889. doi: 10.3389/fonc.2025.1566889. Erratum in: Front Oncol. 2025, 15: 1659429.
[23] Karimi M, Parsania M, Motakef Kazemi N, Qomi M, Hadipour Jahromy M. Curcumin nanoemulsion suppresses HPV oncogenes and inhibits cervical cancer progression: in vitro and in vivo study[J]. Virology Journal, 2025, 22(1): 165. doi: 10.1186/s12985-025-02738-2.
[24] Sarkar E, Kotiya A, Bhuyan R, Raza ST, Misra A, Ahmad R, Mahdi AA. Curcumin chemo-sensitizes intrinsic apoptosis through ROS-mediated mitochondrial hyperpolarization and DNA damage in breast cancer cells[J]. Cellular Signalling, 2025, 128: 111637. doi: 10.1016/j.cellsig.2025.111637.
[25] Li J, Feng S, Wang X, Zhang B, He Q. Exploring the targets and molecular mechanisms of curcumin for the treatment of bladder cancer based on network pharmacology, molecular docking and molecular dynamics[J]. Molecular Biotechnology, 2025, 67(5): 2138-2159. doi: 10.1007/s12033-024-01190-x.
[26] Wang Y, Wang S, Ma C, Qi W, Lv J, Zhang M, Wang S, Wang R, Lu Y, Qiu W. Nrf2 depletion enhanced curcumin therapy effect in gastric cancer by inducing the excessive accumulation of ROS[J]. Scientific Reports, 2024, 14(1): 30165. doi: 10.1038/s41598-024-81375-1.
[27] Zheng F, Lu J, Wang C, Yu H, Fu Y, Ma D. Curcumin enhances ATG3-dependent autophagy and inhibits metastasis in cervical carcinoma[J]. Cell Division, 2024, 19(1): 33. doi: 10.1186/s13008-024-00138-6.
[28] Mahdi Khamaneh A, Jafari-Gharabaghlou D, Ansarin K, Pazooki P, Akbarpour Z, Naghili B, Zarghami N. A new insight into the impact of copy number variations on cell cycle deregulation of luminal-type breast cancer[J]. Oncology Reviews, 2025, 19: 1516409. doi: 10.3389/or.2025.1516409.
[29] Zhang C, Wang H, Lei H, Ou J. Nano-curcumin attenuates tamoxifen resistance and malignant progression in ER-positive breast cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway[J]. The Journal of Steroid Biochemistry and Molecular Biology, 2025, 254: 106825. doi: 10.1016/j.jsbmb.2025.106825.
[30] Rubin SM, Sage J, Skotheim JM. Emerging strategies to inhibit the G1/S transition for cancer therapy[J]. Cancer Research, 2026, 86(7): 1545-1557. doi: 10.1158/0008-5472.CAN-25-0916.
[31] Li Hua-qiang, Jin Li-ji, Wu Fei-fei, et al. Effect of curcumin on proliferation, cell cycle, and caspases in MCF-7 cells[J]. Journal of Dalian University of Technology, 2025.
[32] Moawad M, Altrawy A, Nasr GM, Abd El Aal WS, Nasr MY, Eissa MS, Shaker ES. Comparative multi-pathway inhibition of breast cancer by micro- and nano-formulated curcumin[J]. Molecular Biology Reports, 2026, 53(1): 411. doi: 10.1007/s11033-026-11506-6.
[33] Sirigiripeta S, Dokala A, Anupalli R. Synergistic anticancer potential of phenethyl isothiocyanate and curcumin induces apoptosis and G2/M cell cycle arrest in HER2-positive breast cancer cells[J]. Cytology and Genetics, 2023, 57(6): 611-624.
[34] Givi T, Mohajerani F, Tehrankhah ZM, Karimi Taheri M, Amirahmadi M, Babashah S, Sadeghizadeh M. Nano-curcumin enhances the sensitivity of tamoxifen-resistant breast cancer cells via the Cyclin D1-DILA1 axis and the PI3K/AKT/mTOR pathway downregulation[J]. PLoS One, 2025, 20(12): e0335165. doi: 10.1371/journal.pone.0335165.
[35] Akter K, Gul K, Mumtaz S. Revisiting curcumin in cancer therapy: Recent insights into molecular mechanisms, nanoformulations, and synergistic combinations[J]. Current Issues in Molecular Biology, 2025, 47(9): 716. doi: 10.3390/cimb47090716.
[36] Korucu EN, Aydemir S, Menevse E, Erkoc Kaya D, Azzawri AA. Gene expression of MTATP6 and cytochrome P450 in MCF-7 and MDA-MB-231 breast cancer cell lines with juglone and curcumin supplemented[J]. Nucleosides, Nucleotides & Nucleic Acids, 2025, 44(9): 750-766. doi: 10.1080/15257770.2024.2418907.
[37] Faysal M, Zehravi M, Al Amin M, Sweilam SH, Panigrahy UP, Khan AS, Kar NR, Dash SK, Padhan A, Rab SO, Uddin MZ, Cherrada N, Bin Emran T. Targeting key molecular mechanisms in triple-negative breast cancer therapies with natural compounds[J]. Current Pharmaceutical Design, 2025. doi: 10.2174/0113816128411154250918060514.
[38] Sarkar E, Kotiya A, Bhuyan R, Raza ST, Misra A, Ahmad R, Mahdi AA. Curcumin chemo-sensitizes intrinsic apoptosis through ROS-mediated mitochondrial hyperpolarization and DNA damage in breast cancer cells[J]. Cellular Signalling, 2025, 128: 111637. doi: 10.1016/j.cellsig.2025.111637.
[39] Moawad M, Altrawy A, Nasr GM, Abd El Aal WS, Nasr MY, Eissa MS, Shaker ES. Comparative multi-pathway inhibition of breast cancer by micro- and nano-formulated curcumin[J]. Molecular Biology Reports, 2026, 53(1): 411. doi: 10.1007/s11033-026-11506-6.
[40] Sarkar E, Kotiya A, Bhuyan R, Raza ST, Misra A, Ahmad R, Mahdi AA. Curcumin chemo-sensitizes intrinsic apoptosis through ROS-mediated mitochondrial hyperpolarization and DNA damage in breast cancer cells[J]. Cellular Signalling, 2025, 128: 111637. doi: 10.1016/j.cellsig.2025.111637.
[41] Zou D, Fang Y, Zhu M, Wu C, Huang Y, Ren L, Wei Z, Zou W, Li X, Wu Y, Chen W, Zhao Y, Yu S, Wang A, Lu Y. Synergistic targeting of ITGA5/CCN1 by Sparganii Rhizoma and Curcumae Rhizoma suppresses breast cancer metastasis via angiogenesis and adhesion[J]. Phytomedicine, 2025, 148: 157426. doi: 10.1016/j.phymed.2025.157426.
[42] Ganjipete S, Dinesh BGH, Bandral SK, Ramar M, Ammunje DN, Pavadai P. Nutraceuticals in breast cancer therapy: Mechanistic insights and therapeutic potential[J]. International Journal of Biological Macromolecules, 2025, 333(Pt 2): 148811. doi: 10.1016/j.ijbiomac.2025.148811.
[43] Li M, Guo T, Lin J, Huang X, Ke Q, Wu Y, Fang C, Hu C. Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog/Gli1 signaling pathway[J]. Journal of Ethnopharmacology, 2022, 283: 114689. doi: 10.1016/j.jep.2021.114689. Erratum in: J Ethnopharmacol. 2023, 312: 116524.
[44] Zhou Z, Zhong H, Wang H, Wang S, Kridis WB, Wang R, Shen K, Wang Z, Huang R. Microenvironmental regulation and remodeling of breast cancer angiogenesis: from basic mechanisms to clinical therapeutic implications[J]. Discover Oncology, 2025, 16(1): 1973. doi: 10.1007/s12672-025-03797-1.
[45] Nass N, Ignatov A, Kalinski T. Interplay of interleukin-1β and curcumin on VEGF expression in breast cancer cells[J]. Oncology Research, 2026, 34(3): 13. doi: 10.32604/or.2025.072793.
[46] Dam I, Liu E, Ali A, Madu CO, Lu Y. Natural phytochemicals as inhibitors of HIF-1α in breast cancer: Review of preclinical evidence and future prospects[J]. Current Issues in Molecular Biology, 2026, 48(1): 121. doi: 10.3390/cimb48010121.
[47] Sichetti M, Giuseffi M, Giglio E, Marino G, Mecca M. Effect of natural polyphenols on breast cancer chemoprevention and treatment[J]. Molecular Nutrition & Food Research, 2025, 69(16): e70055. doi: 10.1002/mnfr.70055.
[48] Ferreira LC, Arbab AS, Jardim-Perassi BV, Borin TF, Varma NR, Iskander AS, Shankar A, Ali MM, Zuccari DA. Effect of curcumin on pro-angiogenic factors in the xenograft model of breast cancer[J]. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15(10): 1285-1296. doi: 10.2174/1871520615666150520093644.
[49] Güler AE, Tuncer MC, Özdemir İ. Curcumin enhances gemcitabine sensitivity in breast cancer cells through ROS-associated mitochondrial apoptosis and transcriptional reprogramming[J]. Biology (Basel), 2026, 15(5): 448. doi: 10.3390/biology15050448.
[50] Wang PP, He CX, Shuai YY, Zhang HJ, Zhang L, Ao H, Peng W, Zhang H. The combination of natural products: A promising therapeutical way for management of breast cancers[J]. Phytotherapy Research, 2025, 39(9): 3886-3902. doi: 10.1002/ptr.70044.
[51] Wang Y, Wang Q, Chang J, Chen Z, Qi C, Jiang X, Feng X. Multi-dimensional targeting of the tumor microenvironment to inhibit the invasion and metastasis of breast cancer[J]. Pathology - Research and Practice, 2026, 277: 156309. doi: 10.1016/j.prp.2025.156309.
[52] Golmohammadi M, Zamanian MY, Al-Ani AM, Jabbar TL, Kareem AK, Aghaei ZH, Tahernia H, Hjazi A, Jissir SA, Hakimizadeh E. Targeting STAT3 signaling pathway by curcumin and its analogues for breast cancer: A narrative review[J]. Animal Models and Experimental Medicine, 2024, 7(6): 853-867. doi: 10.1002/ame2.12491.
[53] Hilliard AL, Russell TD, Mendonca P, Soliman KFA. Targeting the tumor immune microenvironment in triple-negative breast cancer: The promise of polyphenols[J]. Cancers (Basel), 2025, 17(17): 2794. doi: 10.3390/cancers17172794.
[54] Wang S, Wang X, Zheng X, Jiang H, Liu L, Ma N, Dong X. NGR-modified curcumin nanovesicles reverse immunotherapy resistance in triple-negative breast cancer via TLR9 and mTOR pathway modulation[J]. Cell Biology and Toxicology, 2025, 41(1): 109. doi: 10.1007/s10565-025-10055-1.
[55] Zhou J, Donatelli SS, Gilvary DL, Tejera MM, Eksioglu EA, Chen X, Coppola D, Wei S, Djeu JY. Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin[J]. Scientific Reports, 2016, 6: 29521. doi: 10.1038/srep29521.
[56] Zheng J, Liu W, Wang X, Li H, Wang Z, Ai Z. Curcumin enhances anti-tumor immunity in anaplastic thyroid carcinoma by elevating CD8+ T cell function and downregulating the AKT/mTORC1/STAT3/PD-L1 axis[J]. Pathology - Research and Practice, 2025, 269: 155898. doi: 10.1016/j.prp.2025.155898.
[57] Jiang M, et al. PI3K/AKT/mTOR axis in cancer: From pathogenesis to treatment[J]. MedComm, 2025, 6(8): e70295.
[58] Wali AF, Talath S, El Tanani M, et al. PI3K/AKT/mTOR pathway in breast cancer pathogenesis and therapy: Insights into phytochemical-based therapeutics[J]. Nutrition and Cancer, 2025. doi: 10.1080/01635581.2025.2521884.
[59] Liao MJ, Chen HF. Research progress on the relationship between PI3K-Akt signaling pathway and breast cancer[J]. Cancer Progress, 2012, 10(2): 135-139.
[60] Zoi V, Kyritsis AP, Galani V, Lazari D, Sioka C, Voulgaris S, Alexiou GA. The role of curcumin in cancer: A focus on the PI3K/Akt pathway[J]. Cancers (Basel), 2024, 16(8): 1554. doi: 10.3390/cancers16081554.
[61] Momal U, Shahbaz M, Perween A, Hassan MHU, Naeem H, Shahid Z, Hussain M, Imran M, Alsagaby SA, Al Abdulmonem W, Abdelgawad MA, Ghoneim MM, FentaYehuala T, Selim S, Mostafa EM. Anticancer molecular mechanisms of curcuminoids: An updated review of clinical trials[J]. Food Science & Nutrition, 2026, 14(2): e71452. doi: 10.1002/fsn3.71452.
[62] Wali AF, Talath S, El Tanani M, et al. PI3K/AKT/mTOR pathway in breast cancer pathogenesis and therapy: Insights into phytochemical-based therapeutics[J]. Nutrition and Cancer, 2025. doi: 10.1080/01635581.2025.2521884.
[63] Faysal M, Zehravi M, Al Amin M, Sweilam SH, Panigrahy UP, Khan AS, Kar NR, Dash SK, Padhan A, Rab SO, Uddin MZ, Cherrada N, Bin Emran T. Targeting key molecular mechanisms in triple-negative breast cancer therapies with natural compounds[J]. Current Pharmaceutical Design, 2025. doi: 10.2174/0113816128411154250918060514.
[64] Zhang Z, Richmond A, Yan C. Immunomodulatory properties of PI3K/AKT/mTOR and MAPK/MEK/ERK inhibition augment response to immune checkpoint blockade in melanoma and triple-negative breast cancer[J]. International Journal of Molecular Sciences, 2022, 23(13): 7353. doi: 10.3390/ijms23137353.
[65] Wang RL, Wang J, Ding H, et al. Mechanism of curcumin inhibiting mouse breast cancer 4T1 cells by up-regulating Bax/Bcl-2 ratio and down-regulating NF-κB p65 expression[J]. Special Wild Economic Animal and Plant Research, 2025, 47(4): 152-157.
[66] Li F, Qi Q, Qiao Y, Huang Y, Lu Y, Gu K, Liu H, Gao C. Curcumenol inhibits malignant progression and promotes ferroptosis via the SLC7A11/NF-κB/TGF-β pathway in triple-negative breast cancer[J]. International Journal of Molecular Medicine, 2025, 56(1): 111. doi: 10.3892/ijmm.2025.5552.
[67] Zhang Z, Richmond A, Yan C. Immunomodulatory properties of PI3K/AKT/mTOR and MAPK/MEK/ERK inhibition augment response to immune checkpoint blockade in melanoma and triple-negative breast cancer[J]. International Journal of Molecular Sciences, 2022, 23(13): 7353. doi: 10.3390/ijms23137353.
[68] Nass N, Ignatov A, Kalinski T. Interplay of interleukin-1β and curcumin on VEGF expression in breast cancer cells[J]. Oncology Research, 2026, 34(3): 13. doi: 10.32604/or.2025.072793.
[69] Sichetti M, Giuseffi M, Giglio E, Marino G, Mecca M. Effect of natural polyphenols on breast cancer chemoprevention and treatment[J]. Molecular Nutrition & Food Research, 2025, 69(16): e70055. doi: 10.1002/mnfr.70055.
[70] Nair B, Menon A, Rithwik Kalidas M, Nath LR, Calina D, Sharifi-Rad J. Modulating the JAK/STAT pathway with natural products: potential and challenges in cancer therapy[J]. Discover Oncology, 2025, 16(1): 595. doi: 10.1007/s12672-025-02369-7.
[71] Montazersaheb S, et al. Targeting STAT3 pathway: A promising immunotherapeutic strategy for triple-negative breast cancer – Current status and future outlooks[J]. European Journal of Pharmacology, 2025.
[72] Lin L, et al. Modulating the JAK/STAT pathway with natural products: potential and challenges in cancer therapy[J]. Discover Oncology, 2025, 16: 595.
[73] Lin L, Hutzen B, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells[J]. Cancer Research, 2010, 70(6): 2445-2454. doi: 10.1158/0008-5472.CAN-09-3768.
[74] Golmohammadi M, et al. Targeting STAT3 signaling pathway by curcumin and its analogues for breast cancer: A narrative review[J]. Animal Models and Experimental Medicine, 2024, 7(6): 853-867. doi: 10.1002/ame2.12491.
[75] Li X, Niu B, Li QH, et al. Curcumin combined with KLF8 gene siRNA regulates the JAK2/STAT3 signaling pathway and inhibits the growth of breast cancer cells[J]. Journal of Anhui Medical University, 2026.
[76] Golmohammadi M, Zamanian MY, Al-Ani AM, Jabbar TL, Kareem AK, Aghaei ZH, Tahernia H, Hjazi A, Jissir SA, Hakimizadeh E. Targeting STAT3 signaling pathway by curcumin and its analogues for breast cancer: A narrative review[J]. Animal Models and Experimental Medicine, 2024, 7(6): 853-867. doi: 10.1002/ame2.12491.
[77] Poma P, Massaro M, Rigogliuso S, Condorelli L, Sánchez-Espejo R, Viseras C, Notarbartolo M, Riela S. Curcumin and doxorubicin encapsulated in biocompatible clay-based nanomaterial: A strategy to overcome multidrug resistance[J]. Archiv der Pharmazie, 2025, 358(1): e2400702. doi: 10.1002/ardp.202400702.
[78] Brodzicka A, Galanty A, Paśko P. Modulation of multidrug resistance transporters by food components and dietary supplements: Implications for cancer therapy efficacy and safety[J]. Current Issues in Molecular Biology, 2024, 46(9): 9686-9706. doi: 10.3390/cimb46090576.
[79] Momal U, Shahbaz M, Perween A, Hassan MHU, Naeem H, Shahid Z, Hussain M, Imran M, Alsagaby SA, Al Abdulmonem W, Abdelgawad MA, Ghoneim MM, FentaYehuala T, Selim S, Mostafa EM. Anticancer molecular mechanisms of curcuminoids: An updated review of clinical trials[J]. Food Science & Nutrition, 2026, 14(2): e71452. doi: 10.1002/fsn3.71452.
[80] Faysal M, Zehravi M, Al Amin M, Sweilam SH, Panigrahy UP, Khan AS, Kar NR, Dash SK, Padhan A, Rab SO, Uddin MZ, Cherrada N, Bin Emran T. Targeting key molecular mechanisms in triple-negative breast cancer therapies with natural compounds[J]. Current Pharmaceutical Design, 2025. doi: 10.2174/0113816128411154250918060514.
[81] Nugroho BE, et al. Effect of Curcuma longa extract on granzyme expression and tumor mass diameter of mammary adenocarcinoma with chemotherapy adriamycin cyclophosphamide: An animal study in rats[J]. Asian Pacific Journal of Cancer Prevention, 2025, 26(9): 3221-3227. doi: 10.31557/APJCP.2025.26.9.3221.
[82] Raeisi E, Heidari-Soureshjani S, Sherwin CM, Lemoigne Y, Mardani-Nafchi H. Advances in radiation therapy enhancement and radio-protection by nano-curcumins: A systematic review[J]. Current Cancer Drug Targets, 2025. doi: 10.2174/0115680096360434250211042759.
[83] Sarkar E, Kotiya A, Bhuyan R, Raza ST, Misra A, Ahmad R, Mahdi AA. Curcumin chemo-sensitizes intrinsic apoptosis through ROS-mediated mitochondrial hyperpolarization and DNA damage in breast cancer cells[J]. Cellular Signalling, 2025, 128: 111637. doi: 10.1016/j.cellsig.2025.111637.
[84] Komar ZM, Ladan MM, Verkaik NS, et al. Curcumin induces homologous recombination deficiency by BRCA2 degradation in breast cancer and normal cells[J]. Cancers, 2025, 17(13): 2109. doi: 10.3390/cancers17132109.
[85] Khanehzar E, Shams F, Jafari A. The golden touch: a comprehensive network pharmacology-guided review of synergy between curcumin and PARP inhibitors[J]. Medical Oncology, 2025, 43(1): 20. doi: 10.1007/s12032-025-03140-2.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 by author(s) and Erytis Publishing Limited.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
How to Cite
